

Extraordinary General Meeting in Forward Pharma A/S

NOTICE TO CONVENE EXTRAORDINARY GENERAL MEETING

An extraordinary general meeting in Forward Pharma A/S will be held on

25 February 2025 at 2.00 pm (CET)

at the offices of Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark.

AGENDA

- (a) Resolution for the voluntary solvent liquidation of the Company
- (b) Authorization of the liquidator

THE AGENDA AND THE COMPLETE PROPOSED RESOLUTIONS

Item (a):

The Board of Directors proposes to pass a resolution for the voluntary solvent liquidation of the Company in accordance with the Danish Companies Act and to appoint Jakob Mosegaard Larsen, attorney-at-law, as liquidator. Further information, along with the basis for the proposal, is provided in [Appendix A](#).

Item (b):

The Board of Directors proposes to authorize the liquidator (with a right of substitution) to apply for registration with the Danish Business Authority of the resolution passed under agenda item (a) and to make any such amendments and supplements to the application and the resolution, including the Company's Articles of Association and minutes of extraordinary general meeting as may be required as a condition for registration.

Majority requirements

The proposal under agenda item (a) may be adopted by at least two-thirds of the votes cast and of the share capital represented at the general meeting. The proposal under agenda item (b) may be adopted by a simple majority of votes.

Share capital

The current share capital of the company is DKK 1,014,735.62 divided into 101,473,562 shares of DKK 0.01 each. Each share of DKK 0.01 carries one vote.

Record date

The record date is 18 February 2025 end of day (CET).

Participation and voting rights

The right of a shareholder to attend and vote at a general meeting is determined by the shares held by the shareholder at the record date.

The number of shares held by each shareholder at the record date shall be calculated based on (i) the number of shares registered in the company's register of shareholders and (ii) any notification of ownership received by the company but not yet registered in the company's register of shareholders.

For practical reasons, shareholders are encouraged to vote by correspondence or submit a proxy to the board of directors in accordance with the instructions below.

The extraordinary general meeting will be conducted in Danish. Participation is conditional on the shareholder having obtained an admission card in due time.

How to obtain an admission card

Access to the extraordinary general meeting is conditional on the shareholder having requested an admission card by 21 February 2025 end of day (CET).

Admission cards for the extraordinary general meeting may be obtained by:

- returning the attached request for admission card form, duly completed and signed, by email to kbo@mazanti.dk or by ordinary letter to Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark, Att. Kristian Bojsen.

How to submit a proxy

Proxies shall be submitted by 24 February 2025 end of day (CET).

Voting instructions by proxy may be completed and submitted by:

- returning the attached proxy form, duly completed and signed, by email to kbo@mazanti.dk or by ordinary letter to Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark, Att. Kristian Bojsen.

From shareholders unable to attend the extraordinary general meeting, the Board of Directors would appreciate receiving a proxy to exercise the voting rights attached to the shares to know the shareholders' view on the respective items on the agenda.

According to Danish law, a proxy issued to the Board of Directors for the extraordinary general meeting is only valid if it is in writing and dated.

How to vote by correspondence

Shareholders may vote by correspondence no later than 24 February 2025 end of day (CET) by:

- returning the attached voting by correspondence form, duly completed and signed, by email to kbo@mazanti.dk or by ordinary letter to Mazanti-Andersen Advokatpartnerselskab, Amaliegade 10, 1265 Copenhagen K, Denmark, Att. Kristian Bojsen.

Votes by correspondence cannot be withdrawn.

Information on the website

Further information on the general meeting will be available on www.forward-pharma.com → 'Investors' until and including the date of the extraordinary general meeting, including:

- The notice convening the general meeting.
- Outline of the total number of shares and voting rights on the date of the notice.
- The agenda and the complete proposals.
- The forms to be used for voting by proxy or voting by correspondence.

10 February 2025

The Board of Directors of Forward Pharma A/S